{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:13:24Z","timestamp":1793873604693,"version":"4.6.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,4,20]],"date-time":"2016-04-20T00:00:00Z","timestamp":1461110400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s40268-016-0134-z","type":"journal-article","created":{"date-parts":[[2016,4,20]],"date-time":"2016-04-20T06:23:23Z","timestamp":1461133403000},"page":"239-249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Na\u00efve Patients with Type 2 Diabetes Mellitus"],"prefix":"10.1007","volume":"16","author":[{"given":"Changyu","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge L.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte Thim","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,20]]},"reference":[{"key":"134_CR1","unstructured":"International Diabetes Foundation. Diabetes atlas. 7th edition 2015. Available from http:\/\/www.idf.org\/diabetesatlas . Accessed 18 Feb 2016."},{"key":"134_CR2","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jama.2013.168118","volume":"310","author":"Y Xu","year":"2013","unstructured":"Xu Y, Wang L, He J, et al. 2010 China Noncommunicable Disease Surveillance Group. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310:948\u201359.","journal-title":"JAMA."},{"key":"134_CR3","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577\u201389.","journal-title":"N Engl J Med."},{"key":"134_CR4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.diabet.2014.08.006","volume":"40","author":"M Hanefeld","year":"2014","unstructured":"Hanefeld M. Use of insulin in type 2 diabetes: what we learned from recent clinical trials on the benefits of early insulin initiation. Diabetes Metab. 2014;40:391\u20139.","journal-title":"Diabetes Metab."},{"key":"134_CR5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00125-014-3460-0","volume":"58","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58:429\u201342.","journal-title":"Diabetologia."},{"key":"134_CR6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/VHRM.S33934","volume":"9","author":"B Ahr\u00e9n","year":"2013","unstructured":"Ahr\u00e9n B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag. 2013;9:155\u201363.","journal-title":"Vasc Health Risk Manag."},{"key":"134_CR7","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s40262-014-0165-y","volume":"53","author":"H Haahr","year":"2014","unstructured":"Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014;53:787\u2013800.","journal-title":"Clin Pharmacokinet."},{"key":"134_CR8","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.2337\/dc12-2329","volume":"36","author":"SC Gough","year":"2013","unstructured":"Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Low-volume insulin degludec 200 units\/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care. 2013;36:2536\u201342.","journal-title":"Diabetes Care."},{"key":"134_CR9","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/jdi.12102","volume":"4","author":"Y Onishi","year":"2013","unstructured":"Onishi Y, Iwamoto Y, Yoo SJ, Clauson P, Tamer SC, Park S. Insulin degludec compared with insulin glargine in insulin-na\u00efve patients with type 2 diabetes: a 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Investig. 2013;4:605\u201312.","journal-title":"J Diabetes Investig."},{"key":"134_CR10","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.2337\/dc12-1205","volume":"35","author":"B Zinman","year":"2012","unstructured":"Zinman B, Philis-Tsimikas A, Cariou B, et al. NN1250-3579 (BEGIN Once Long) Trial Investigators. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35:2464\u201371.","journal-title":"Diabetes Care."},{"key":"134_CR11","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(12)60205-0","volume":"379","author":"AJ Garber","year":"2012","unstructured":"Garber AJ, King AB, Del Prato S, et al. NN1250-3582 (BEGIN BB T2D) Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379:1498\u2013507.","journal-title":"Lancet."},{"issue":"2","key":"134_CR12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s13300-014-0076-9","volume":"5","author":"J Vora","year":"2014","unstructured":"Vora J, Christensen T, Rana A, Bain SC. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes Ther. 2014;5(2):435\u201346.","journal-title":"Diabetes Ther."},{"key":"134_CR13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/dom.12032","volume":"15","author":"RE Ratner","year":"2013","unstructured":"Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15:175\u201384.","journal-title":"Diabetes Obes Metab."},{"key":"134_CR14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1477-7525-7-83","volume":"7","author":"M Brod","year":"2009","unstructured":"Brod M, Hammer M, Christensen T, Lessard S, Bushnell DM. Understanding and assessing the impact of treatment in diabetes: the Treatment-Related Impact Measures for Diabetes and Devices (TRIM-Diabetes and TRIM-Diabetes Device). Health Qual Life Outcomes. 2009;7:83.","journal-title":"Health Qual Life Outcomes."},{"key":"134_CR15","unstructured":"Warren M, Chaykin LB, Jabbour SA, et al. Efficacy, patient-reported outcomes (PRO) and safety of insulin degludec U200 vs. insulin glargine in patients with type 2 diabetes (T2D) requiring high-dose insulin (Poster 1040-P). Presented at the American Diabetes Association, 75th Annual Scientific Sessions; 2015 June 5\u20139; Boston, MA, USA. Available from: https:\/\/ada.scientificposters.com\/epsSearchADA.cfm . Accessed 18 Aug 2015."},{"key":"134_CR16","doi-asserted-by":"crossref","unstructured":"World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. Seoul: 59th WMA General Assembly; 2008.","DOI":"10.1515\/9783110208856.233"},{"key":"134_CR17","unstructured":"International Conference on Harmonisation. ICH harmonised tripartite guideline: Guideline for Good Clinical Practice E6 (R1), Step 4; 1996."},{"key":"134_CR18","unstructured":"Turner-Bowker DM, Bartley PJ, Ware JE. SF-36\u00ae Health survey and \u201cSF\u201d bibliography. Third Edition (1988\u20132000). Lincoln: QualityMetric Incorporated; 2002."},{"key":"134_CR19","doi-asserted-by":"crossref","first-page":"876","DOI":"10.2337\/diacare.25.5.876","volume":"25","author":"A Lindholm","year":"2002","unstructured":"Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, R\u00e5stam J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care. 2002;25:876\u201382.","journal-title":"Diabetes Care."},{"key":"134_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2004.06.002","volume":"289","author":"AR Mire-Sluis","year":"2004","unstructured":"Mire-Sluis AR, Barrett YC, Devanarayan V, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods. 2004;289:1\u201316.","journal-title":"J Immunol Methods."},{"key":"134_CR21","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.2337\/dc15-0808","volume":"38","author":"DB Muchmore","year":"2015","unstructured":"Muchmore DB, Heinemann L, Tamborlane W, Wu XW, Fleming A. Assessing rates of hypoglycemia as an end point in clinical trials. Diabetes Care. 2015;38:e160\u20131.","journal-title":"Diabetes Care."},{"key":"134_CR22","unstructured":"FDA, USDHHS, and CDER. Guidance for industry: diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention, 2008. Available from http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm071624.pdf . Accessed 18 Aug 2015."},{"key":"134_CR23","doi-asserted-by":"crossref","first-page":"e1454","DOI":"10.1136\/bmj.e1454","volume":"344","author":"EA Hu","year":"2012","unstructured":"Hu EA, Pan A, Malik V, Sun Q. White rice consumption and risk of type 2 diabetes: meta-analysis and systematic review. BMJ. 2012;344:e1454.","journal-title":"BMJ."},{"key":"134_CR24","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/dme.13002","volume":"33","author":"S Heller","year":"2016","unstructured":"Heller S, Mathieu C, Kapur R, Wolden ML, Zinman B. A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia. Diabet Med. 2016;33:478\u201387.","journal-title":"Diabet Med"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-016-0134-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-016-0134-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-016-0134-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T17:51:11Z","timestamp":1567792271000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-016-0134-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,20]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["134"],"URL":"https:\/\/doi.org\/10.1007\/s40268-016-0134-z","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,20]]}}}